Cholestasis-reducing effects of bezafibrate on survivors of biliary atresia with native livers: A prospective phase II trial
BZF decreased cholestasis markers in survivors of BA with native livers, indicating its potential as an alternative to delayed liver transplantation for this population.
Authors
- Tomoro Hishiki (ORCID: https://orcid.org/0000-0002-2515-1054)
- Takayuki Kondo (ORCID: https://orcid.org/0000-0002-1075-9876)
- K. Terui
- Takashi Fumita
- Hiroko Yoshizawa
- Yunosuke Kawaguchi
- Sadahisa Ogasawara (ORCID: https://orcid.org/0000-0002-6540-9064)
- Y. Ozawa
- YOSUKE INABA
- Ryohei Shibata
Institutions
- Chiba University (JP)
- Chiba University Hospital (JP)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1097/hc9.0000000000000877
- Primary Topic
- Pediatric Hepatobiliary Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00